Chemotherapy for Hodgkin's lymphoma in a patient receiving clozapine for treatment-resistant schizophrenia: use of the Mental Capacity Act 2005
| Autor: | Jan Falkowski, Nicholas Walsh, Florence Elizabeth Chamberlain |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Current Practice
Chemotherapy Pediatrics medicine.medical_specialty business.industry medicine.medical_treatment Hodgkin's lymphoma medicine.disease 030227 psychiatry Lymphoma 03 medical and health sciences Psychiatry and Mental health 0302 clinical medicine immune system diseases Schizophrenia hemic and lymphatic diseases 030220 oncology & carcinogenesis Immunology Mental capacity medicine Treatment resistant schizophrenia Treatment resistance business Clozapine medicine.drug |
| Zdroj: | BJPsych Bulletin |
| ISSN: | 2056-4708 2056-4694 |
| DOI: | 10.1192/pb.bp.114.048306 |
| Popis: | SummaryTreatment resistance occurs in approximately 30% of individuals with schizophrenia and is commonly treated with clozapine. Nodular sclerosing Hodgkin's lymphoma is a subtype of Hodgkin's lymphoma predominantly affecting those under 50 years of age. In this case report, an individual with treatment-resistant schizophrenia developed nodular sclerosing Hodgkin's lymphoma and is treated with concurrent clozapine and systemic chemotherapy. The aim of this case report is to act as guidance for clinicians and to outline the difficulties of treating individuals with psychiatric illness under the Mental Capacity Act 2005 when the proposed treatment could lead to high levels of morbidity and mortality. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|